SERPINA9抗体;SERPINA9 Antibody—艾普蒂 新品

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Raji cell lysate, Primary antibody: P13453(SERPINA9 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P13453(SERPINA9 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

SERPINA9. also known as centraxin (CENP), is a member of the serine protease inhibitor (serpin) superfamily, which regulates proteolytic enzymes involved in diverse physiological processes. The SERPINA9 gene encodes a glycoprotein predominantly expressed in B lymphocytes and plasma cells, suggesting a role in immune regulation. Studies link SERPINA9 to B-cell development, differentiation, and survival, with elevated expression observed in germinal center B-cells and certain B-cell malignancies, such as diffuse large B-cell lymphoma (DLBCL). Its precise biological function remains under investigation, but it may modulate apoptosis and inflammatory responses by inhibiting target proteases.

SERPINA9 antibodies are immunological tools used to detect and study the protein's expression, localization, and interactions in research contexts. They are employed in techniques like Western blotting, immunohistochemistry, and flow cytometry to explore SERPINA9's role in immune disorders and cancers. Clinically, SERPINA9 has been investigated as a potential biomarker for disease prognosis, particularly in lymphoproliferative disorders, where its expression patterns correlate with tumor aggressiveness or treatment response. However, its therapeutic relevance remains exploratory, with ongoing studies aiming to clarify its mechanistic pathways and validate its utility as a diagnostic or therapeutic target.